{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:40:14Z","timestamp":1791916814950,"version":"4.3.4"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.biopha.2021.112107","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T01:22:31Z","timestamp":1630027351000},"page":"112107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Recent advances in management of COVID-19: A review"],"prefix":"10.1016","volume":"143","author":[{"given":"Soraya","family":"Mouffak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qamar","family":"Shubbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekram","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raafat","family":"El-Awady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112107_bib1","unstructured":"Situational report. World Health organization 2021."},{"key":"10.1016\/j.biopha.2021.112107_bib2","unstructured":"About the virus. World Health organization 2020."},{"issue":"3","key":"10.1016\/j.biopha.2021.112107_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/JCMA.0000000000000270","article-title":"The outbreak of COVID-19: an overview","volume":"83","author":"Wu","year":"2020","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.biopha.2021.112107_bib4","series-title":"Coronaviruses\u2014A General Introduction","author":"Aronson","year":"2020"},{"issue":"17","key":"10.1016\/j.biopha.2021.112107_bib5","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1111\/febs.15369","article-title":"Understanding SARS\u2010CoV\u20102 endocytosis for COVID\u201019 drug repurposing","volume":"287","author":"Glebov","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2021.112107_bib6","unstructured":"National Guidelines for Clinical Management and Treatment of COVID-19. 2020 1 June."},{"key":"10.1016\/j.biopha.2021.112107_bib7","unstructured":"Coronavirus (COVID-19) vaccine. U.S. Food and Drug Administration 2021 April 13,."},{"issue":"7","key":"10.1016\/j.biopha.2021.112107_bib8","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS\u2010CoV\u20102 in Wuhan, China","volume":"75","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.biopha.2021.112107_bib9","doi-asserted-by":"crossref","first-page":"m606","DOI":"10.1136\/bmj.m606","article-title":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series","author":"Xu","year":"2020","journal-title":"Br. Med. J."},{"key":"10.1016\/j.biopha.2021.112107_bib10","unstructured":"Cohen P., Blau J., Bloom A. COVID-19: Outpatient evaluation and management of acute illness in adults."},{"key":"10.1016\/j.biopha.2021.112107_bib11","first-page":"5","article-title":"COVID-19 infection: the perspective on immune response","volume":"27","author":"Yufang","year":"2020","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20139-7","article-title":"Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection","volume":"11","author":"Desai","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19706-9","article-title":"Immune suppression in the early stage of COVID-19 disease","volume":"11","author":"Tian","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2021.112107_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res"},{"issue":"2","key":"10.1016\/j.biopha.2021.112107_bib15","first-page":"317","article-title":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","volume":"8","author":"Juarez","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2021.112107_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41429-020-0336-z","article-title":"Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen","volume":"73","author":"Heidary","year":"2020","journal-title":"J. Antibiot."},{"key":"10.1016\/j.biopha.2021.112107_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2021.112107_bib18","doi-asserted-by":"crossref","unstructured":"Scheim D. Ivermectin for COVID-19 treatment: clinical response at quasi-threshold doses via hypothesized alleviation of CD147-mediated vascular occlusion. Available at SSRN 3636557 2020.","DOI":"10.2139\/ssrn.3636557"},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chest.2020.10.009","article-title":"Use of ivermectin is associated with lower mortality in hospitalized patients with Coronavirus Disease 2019: The ivermectin in COVID nineteen study","volume":"159","author":"Rajter","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.biopha.2021.112107_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3329\/jbcps.v38i0.47514","article-title":"Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients","author":"Rahman","year":"2020","journal-title":"J. Bangladesh Coll. Physicians Surg."},{"key":"10.1016\/j.biopha.2021.112107_bib21","doi-asserted-by":"crossref","unstructured":"Behera P., Patro BK, Singh AK, Chandanshive PD, Ravikumar SR, Pradhan SK, et al. Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study. medRxiv 2020.","DOI":"10.1101\/2020.10.29.20222661"},{"issue":"2","key":"10.1016\/j.biopha.2021.112107_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/ph14020092","article-title":"Monoclonal antibodies as neurological therapeutics","volume":"14","author":"Gklinos","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00000441-200207000-00004","article-title":"Therapeutic applications of monoclonal antibodies","volume":"324","author":"Berger","year":"2002","journal-title":"Am. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2021.112107_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13205-021-02647-5","article-title":"Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19)","volume":"11","author":"Bessalah","year":"2021","journal-title":"3 Biotech"},{"issue":"2","key":"10.1016\/j.biopha.2021.112107_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2020.10245","article-title":"Monoclonal antibodies for prevention and treatment of COVID-19","volume":"324","author":"Marovich","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2021.112107_bib26","unstructured":"Monoclonal antibodies. COVID-19 Real-Time Learning Networking 2021."},{"key":"10.1016\/j.biopha.2021.112107_bib27","unstructured":"Fact sheet got health care providers Emergency Use Authorization (EUA) casirivimab and imdevimab. Fda.gov. 2021."},{"key":"10.1016\/j.biopha.2021.112107_bib28","unstructured":"Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19. 2021."},{"key":"10.1016\/j.biopha.2021.112107_bib29","unstructured":"Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab. Fda.gov. 2021 April 16,."},{"key":"10.1016\/j.biopha.2021.112107_bib30","unstructured":"Fact sheet got health care providers Emergency Use Authorization (EUA) of bamlanivimab. Fda.gov. 2021."},{"key":"10.1016\/j.biopha.2021.112107_bib31","unstructured":"FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants for monoclonal antibody products under emergency use authorization. Fda.gov. 2021."},{"issue":"10","key":"10.1016\/j.biopha.2021.112107_bib32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jama.2021.1225","article-title":"Monoclonal Antibodies for COVID-19","volume":"325","author":"Lloyd","year":"2021","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2021.112107_bib33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMe2034495","article-title":"Monoclonal antibodies to disrupt progression of early covid-19 infection","volume":"384","author":"Cohen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112107_bib34","unstructured":"Nevan J., Krogan;\u2021, Schoof. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike Downloaded from. QCRG Structural Biology Consortium 2020;13."},{"issue":"2","key":"10.1016\/j.biopha.2021.112107_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5301\/jbm.5000063","article-title":"Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells","volume":"29","author":"Zare","year":"2014","journal-title":"Int. J. Biol. Markers"},{"issue":"10","key":"10.1016\/j.biopha.2021.112107_bib36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41577-020-00443-5","article-title":"Inhaled nanobodies against COVID-19","volume":"20","author":"Martinez-Delgado","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2021.112107_bib37","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.biopha.2021.112107_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-animal-021419-083831","article-title":"Applications of nanobodies","volume":"9","author":"Muyldermans","year":"2021","journal-title":"Annu. Rev. Anim. Biosci."},{"issue":"6","key":"10.1016\/j.biopha.2021.112107_bib39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2217\/nnm.13.86","article-title":"Nanobodies and their potential applications","volume":"8","author":"Hassanzadeh-Ghassabeh","year":"2013","journal-title":"Nanomedicine"},{"issue":"9","key":"10.1016\/j.biopha.2021.112107_bib40","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","article-title":"Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2","volume":"27","author":"Huo","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6523","key":"10.1016\/j.biopha.2021.112107_bib41","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.abe4747","article-title":"Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2","volume":"370","author":"Xiang","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.biopha.2021.112107_bib42","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"22","key":"10.1016\/j.biopha.2021.112107_bib43","doi-asserted-by":"crossref","first-page":"eabh0319","DOI":"10.1126\/sciadv.abh0319","article-title":"Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses","volume":"7","author":"Nambulli","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib44","first-page":"1","article-title":"A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2021.112107_bib45","doi-asserted-by":"crossref","unstructured":"Pymm P., Adair A., Chan L., Cooney JP, Mordant FL, Allison CC, et al. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proceedings of the National Academy of Sciences 2021;118(19).","DOI":"10.1073\/pnas.2101918118"},{"issue":"6523","key":"10.1016\/j.biopha.2021.112107_bib46","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.abe3255","article-title":"An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike","volume":"370","author":"Schoof","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib47","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/22221751.2020.1768806","article-title":"Development of multi-specific humanized llama antibodies blocking SARS-CoV-2\/ACE2 interaction with high affinity and avidity","volume":"9","author":"Dong","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18387-8","article-title":"Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain","volume":"11","author":"Chi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2021.112107_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.633680","article-title":"COVID-19: famotidine, histamine, mast cells, and mechanisms","volume":"12","author":"Malone","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2021.112107_bib50","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/gutjnl-2020-321852","article-title":"Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series","volume":"69","author":"Janowitz","year":"2020","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.biopha.2021.112107_bib51","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1053\/j.gastro.2020.05.053","article-title":"Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study","volume":"159","author":"Freedberg","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2021.112107_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101942","article-title":"Dual-histamine receptor blockade with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients","volume":"63","author":"Hogan Ii","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2021.112107_bib53","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.14309\/ajg.0000000000000832","article-title":"Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19","volume":"115","author":"Mather","year":"2020","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112107_bib54","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2021.112107_bib55","doi-asserted-by":"crossref","unstructured":"Loffredo M., Lucero H., Chen D., O'Connell A., Bergqvist S., Munawar A., et al. The Effect of famotidine on SARS-CoV-2 proteases and virus replication. bioRxiv 2020.","DOI":"10.1101\/2020.07.15.203059"},{"issue":"5","key":"10.1016\/j.biopha.2021.112107_bib56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical\u2013therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.biopha.2021.112107_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107018","article-title":"Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease","volume":"89","author":"Samaee","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2021.112107_bib58","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2021.112107_bib59","unstructured":"Horby PW, Pessoa-Amorim G., Peto L., Brightling CE, Sarkar R., Thomas K., et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. Medrxiv 2021."},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112107_bib61","unstructured":"A.C. Gordon, P.R. Mouncey, F. Al-Beidh, K.M. Rowan, A.D. Nichol, Y.M. Arabi, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19\u2013Preliminary report. medRxiv 2021:2021.01. 07.21249390."},{"key":"10.1016\/j.biopha.2021.112107_bib62","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3126\/jbs.v7i1.29849","article-title":"COVID-19: recent advances in epidemiology, virology, etiopathogenesis, clinical trials and vaccine development","volume":"7","author":"Banerjee","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2021.112107_bib64","first-page":"1","article-title":"Dexamethasone for the treatment of coronavirus disease (COVID-19): a review","author":"Ahmed","year":"2020","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.biopha.2021.112107_bib65","unstructured":"A. Hodgens, T. Sharman, Corticosteroids. StatPearls [Internet] 2020."},{"key":"10.1016\/j.biopha.2021.112107_bib66","article-title":"A review of the evidence for corticosteroids in COVID-19","author":"Johns","year":"2021","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.biopha.2021.112107_bib67","first-page":"1","article-title":"Dexamethasone for the treatment of coronavirus disease (COVID-19): a review","author":"Ahmed","year":"2020","journal-title":"SN Compr. Clin. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib68","first-page":"1","article-title":"Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials","volume":"7","author":"Raju","year":"2021","journal-title":"Fut. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2021.112107_bib69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jointm.2021.01.002","article-title":"Corticosteroids for COVID-19","volume":"1","author":"Annane","year":"2021","journal-title":"J. Intensive Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.112107_bib70","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams","year":"2018","journal-title":"Respir. Care"},{"key":"10.1016\/j.biopha.2021.112107_bib71","first-page":"10","article-title":"Deciphering the binding mechanism of Dexamethasone against SARS-CoV-2 main protease: computational molecular modelling approach","author":"Khan","year":"2020","journal-title":"ChemRxivorg"},{"issue":"13","key":"10.1016\/j.biopha.2021.112107_bib72","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"8","key":"10.1016\/j.biopha.2021.112107_bib73","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Wootton","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112107_bib74","doi-asserted-by":"crossref","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. NEJM 2021 Feb 25,;384:693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"10.1016\/j.biopha.2021.112107_bib75","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fnins.2019.00862","article-title":"Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases","volume":"13","author":"Ryskamp","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2021.112107_bib76","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.nbd.2013.10.010","article-title":"Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation","volume":"62","author":"Peviani","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2021.112107_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.582310","article-title":"Repurposing sigma-1 receptor ligands for Covid-19 therapy?","volume":"11","author":"Vela","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2021.112107_bib78","doi-asserted-by":"crossref","first-page":"eaau5266","DOI":"10.1126\/scitranslmed.aau5266","article-title":"Modulation of the sigma-1 receptor\u2013IRE1 pathway is beneficial in preclinical models of inflammation and sepsis","volume":"11","author":"Rosen","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2021.112107_bib79","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3389\/fphys.2020.00747","article-title":"COVID-19 sepsis and microcirculation dysfunction","volume":"11","author":"Colantuoni","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2021.112107_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100057","article-title":"Viral sepsis is a complication in patients with Novel Corona Virus Disease (COVID-19)","volume":"8","author":"Liu","year":"2020","journal-title":"Med. Drug Discov."},{"issue":"10223","key":"10.1016\/j.biopha.2021.112107_bib81","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.112107_bib82","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.biopha.2021.112107_bib83","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.biopha.2021.112107_bib84","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1681\/ASN.2018101032","article-title":"Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis","volume":"30","author":"Assimon","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"issue":"14","key":"10.1016\/j.biopha.2021.112107_bib85","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.3390\/ijms21144953","article-title":"COVID-19\/SARS-CoV-2 infection: lysosomes and lysosomotropism implicate new treatment strategies and personal risks","volume":"21","author":"Blaess","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.112107_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.595888","article-title":"Role of endolysosomes in severe acute respiratory syndrome coronavirus-2 infection and coronavirus disease 2019 pathogenesis: implications for potential treatments","volume":"11","author":"Khan","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112107_bib87","doi-asserted-by":"crossref","first-page":"771","DOI":"10.31925\/farmacia.2020.5.1","article-title":"Lysosomotropic properties of sodium bicarbonate and covid-19","volume":"68","author":"Mir","year":"2020","journal-title":"Farmacia"},{"key":"10.1016\/j.biopha.2021.112107_bib88","article-title":"Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19","volume":"130","author":"Norinder","year":"2020","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib89","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/22221751.2020.1829082","article-title":"Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine","volume":"9","author":"Schloer","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000315101","article-title":"Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications","volume":"26","author":"Kornhuber","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"issue":"8","key":"10.1016\/j.biopha.2021.112107_bib91","article-title":"Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells","volume":"1","author":"Carpinteiro","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.biopha.2021.112107_bib92","doi-asserted-by":"crossref","unstructured":"A.R. Eugene, Fluoxetine pharmacokinetics and tissue distribution suggest a possible role in reducing SARS-CoV-2 titers. medRxiv 2020.","DOI":"10.1101\/2020.12.17.20248442"},{"key":"10.1016\/j.biopha.2021.112107_bib93","doi-asserted-by":"crossref","unstructured":"N. Hoertel, M.S. Rico, R. Vernet, N. Beeker, A. Jannot, A. Neuraz, et al. Association between SSRI antidepressant use and reduced risk of intubation or death in hospitalized patients with coronavirus disease 2019: A multicenter retrospective observational study. MedRxiv 2020.","DOI":"10.1101\/2020.07.09.20143339"},{"key":"10.1016\/j.biopha.2021.112107_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117583","article-title":"COVID-19: melatonin as a potential adjuvant treatment","volume":"250","author":"Zhang","year":"2020","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.biopha.2021.112107_bib95","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00213-020-05753-z","article-title":"Fluvoxamine, melatonin and COVID-19","volume":"238","author":"Anderson","year":"2021","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112107_bib96","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/jcp.1041430122","article-title":"Distinct genomic copy number in mitochondria of different mammalian organs","volume":"143","author":"Veltri","year":"1990","journal-title":"J. Cell Physiol."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2021.112107_bib97","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.21037\/jtd.2019.12.85","article-title":"Melatonin for the treatment of sepsis: the scientific rationale","volume":"12","author":"Biancatelli","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2021.112107_bib98","doi-asserted-by":"crossref","first-page":"264","DOI":"10.32794\/mr11250061","article-title":"Protection by melatonin in respiratory diseases: valuable information for the treatment of COVID-19","volume":"3","author":"Hardeland","year":"2020","journal-title":"Melatonin Res."},{"key":"10.1016\/j.biopha.2021.112107_bib99","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1007\/s11033-020-05830-8","article-title":"Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147)","volume":"47","author":"Sehirli","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2021.112107_bib100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fmed.2020.00226","article-title":"Therapeutic algorithm for use of melatonin in patients with COVID-19","volume":"7","author":"Reiter","year":"2020","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.112107_bib101","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1600-079X.2005.00265.x","article-title":"Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro\u2010\/anti\u2010inflammatory cytokine network, protection against oxidative damage and anti\u2010apoptotic effects","volume":"39","author":"Carrillo-Vico","year":"2005","journal-title":"J. Pineal Res."},{"issue":"11","key":"10.1016\/j.biopha.2021.112107_bib102","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.exger.2006.09.002","article-title":"Age-dependent lipopolysaccharide-induced iNOS expression and multiorgan failure in rats: effects of melatonin treatment","volume":"41","author":"Escames","year":"2006","journal-title":"Exp. Gerontol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112107_bib103","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3906\/sag-2005-356","article-title":"Melatonin, aging, and COVID-19: could melatonin be beneficial for COVID-19 treatment in the elderly?","volume":"50","author":"\u00d6zt\u00fcrk","year":"2020","journal-title":"Turk. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.112107_bib104","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-079X.1993.tb00498.x","article-title":"Melatonin, hydroxyl radical\u2010mediated oxidative damage, and aging: a hypothesis","volume":"14","author":"Poeggeler","year":"1993","journal-title":"J. Pineal Res."},{"issue":"3","key":"10.1016\/j.biopha.2021.112107_bib105","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.1111\/jpi.12683","article-title":"Clinical trial to test the efficacy of melatonin in COVID\u201019","volume":"69","author":"Acu\u00f1a\u2010Castroviejo","year":"2020","journal-title":"J. Pineal Res."},{"issue":"4","key":"10.1016\/j.biopha.2021.112107_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijmm.2021.4880","article-title":"Pineal hormone melatonin as an adjuvant treatment for COVID 19","volume":"47","author":"Vlachou","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2021.112107_bib107","doi-asserted-by":"crossref","unstructured":"Eudract_number: 2020 001530 35. EU Clinical Trials Register. 2020.","DOI":"10.5553\/RM\/0920055X2020035006007"},{"issue":"5","key":"10.1016\/j.biopha.2021.112107_bib108","doi-asserted-by":"crossref","first-page":"654","DOI":"10.17269\/s41997-020-00382-7","article-title":"Sleep and circadian rhythm in response to the COVID-19 pandemic","volume":"111","author":"Morin","year":"2020","journal-title":"Can. J. Public Health"},{"key":"10.1016\/j.biopha.2021.112107_bib109","first-page":"1","article-title":"Elderly as a high-risk group during COVID-19 pandemic: effect of circadian misalignment, sleep dysregulation and melatonin administration","author":"Cardinali","year":"2020","journal-title":"Sleep Vigil."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100891X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100891X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:48:45Z","timestamp":1771919325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222100891X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":109,"alternative-id":["S075333222100891X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112107","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in management of COVID-19: A review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112107"}}